Dapagliflozin reduces loop diuretic requirement over time in patients with heart failure with mildly reduced or preserved ejection fraction in the DELIVER Trial
Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)
0
follower
6
more
presentations
in this session
Real-world use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and reduced ejection fraction: data from the Swedish heart failure registry
Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction results from the EMPULSE trial.
Safety of continuing mineralocorticoid receptor antagonists treatment in patients with heart failure with reduced ejection fraction and severe kidney disease: data from swedish heart failure registry
Mineralocorticoid receptor antagonist initiation during admission is associated with improved outcomes irrespective of ejection fraction in patients with acute heart failure
Impact of lower systolic blood pressure on efficacy and safety of sacubitri/valsartan compared to ramipril in patients with acute myocardial infarction: insights from PARADISE-MI trial